17/11/2021 - Press release
Hospital del Mar, in collaboration with Roche, is working on a pioneering artificial intelligence tool to improve the diagnosis and prognosis of patients with small cell lung cancer, one of the cancers with the worst outlook. Based on digitised images from patient biopsies and survival data, the aim is to test whether the tool can reliably predict the benefit of the various treatments. This would allow more effective selection of the most appropriate type of treatment. At a later stage, the aim is to evaluate the specific mutations present in each tumour and to analyse whether digital imaging is capable of predicting these. Hospital del Mar, in collaboration with Roche, has initiated the development of a pioneering artificial intelligence device to improve the diagnosis and prognosis of patients suffering small cell lung cancer. This is one of the lung cancers with the worst prognosis and having such a reliable tool will allow medical teams to determine the best treatment for each type of patient.
Més informació "Artificial intelligence for selecting the best lung cancer treatment"
18/11/2021 - Press release
A study by researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute and Hospital Son Espases, shows that the combination of a new antibiotic, ceftazidime/avibactam, with other antibiotics, can treat infections caused by variants of Pseudonomas aeruginosa that are resistant to all existing treatments. The study, published in Microbiology Spectrum, involved an in vitro analysis of the efficacy of the different treatments and their combinations to determine their effectiveness against variants of this bacterium, which is resistant to all existing drugs. Resistance to antibiotics has been identified by the World Health Organisation as one of the main threats to global health. Infection with Pseudomonas aeruginosa can cause pneumonia, heart problems and sepsis, especially in immunocompromised people
According to a study by the Hospital del Mar Medical Research Institute and the Germans Trias i Pujol Institute of Health Sciences published in the International Journal of Neuropsychopharmacology, driving after drinking alcohol mixed with energy drinks can give the driver a false sense of security, thus increasing the chances of driving while intoxicated and suffering an accident Due to their high caffeine content, energy drinks reduce the sedative effect of alcohol, despite not affecting its negative effects on driving ability Moreover, combining the two drinks increases blood concentrations of alcohol and caffeine. Researchers warn that these effects may favour alcohol intoxication in people with a lower tolerance to these drinks
Més informació "Mixing energy drinks with alcohol can increase the risk of a traffic accident"
09/11/2021 - Press release
A multicentre study published in the journal Biomedicines led by the Hospital del Mar Medical Research Institute reveals that bronchiectasis affects women less severely than it does men. This is a highly prevalent lung disease that causes abundant accumulation of secretions in the lungs The study analysed data from more than 2,000 patients from the Spanish Computerised Registry of Patients with Bronchiectasis (RIBRON). A second study, published in the International Journal of Environmental Research and Public Health, determines the role of eosinophils, immune system cells, as predictors of severity in this type of patient
26/10/2021 - Press release
The risk of death from any cause increases by 30% for each 10 beat per minute increase above 70 beats per minute The study, led by researchers at the Hospital del Mar Medical Research Institute, analysed data from more than 10,000 participants in the REGICOR study to establish the relationship between heart rate and the risk of cardiovascular disease and death It is a simple measurement indicator, which also provides information on the risk of cardiovascular disease. The work has been published in the European Journal of Preventive Cardiology
Més informació "A higher heart rate is associated with a greater risk of death"
19/10/2021 - Press release
Activating a molecule present in the membrane of NK lymphocytes (Natural Killer cells) makes them resistant to the immunosuppressive mechanisms of HER2-positive breast tumours and enhances their antitumour action. Combining standard treatments for HER2-positive breast cancer with drugs that target this molecule in NK cells could increase their clinical efficacy. This paves the way for a new approach to treating this type of tumour with immunotherapy This has been demonstrated in a collaborative study led by researchers at the Hospital del Mar Medical Research Institute, published in the journal Cancer Immunology Research
These are obese patients with no associated diseases, referred to as metabolically healthy, who account for one in five people who undergo bariatric surgery. Their levels of cholesterol, glucose, triglycerides and fatty liver markers continue to fall five years after surgery The improvement is less than that seen in obese patients who do have metabolic problems prior to undergoing surgery and who, therefore, start from higher levels, but it demonstrates the usefulness of applying this surgical procedure to these individuals This has been demonstrated in a study by the Endocrinology and Nutrition Service at Hospital del Mar, the first in Spain, published in the journal Surgery for Obesity and Related Diseases
Més informació "Bariatric surgery improves long-term health of metabolically healthy obese patients"
1/10/2021 - Press release
Patients with chronic obstructive pulmonary disease (COPD) who also suffer from a blood iron deficiency significantly improve their physical fitness if they receive supplements of this mineral. This is a new approach to the disease, which has been validated by the first studies published in Spain in this field and the largest in the world, to date, involving 66 patients. The work, derived from the FACE-Ferinject Assessment study on improving Exercise Tolerance in patients suffering COPD and iron deficiency, was carried out by doctors and researchers in the Pneumology Department at Hospital del Mar and the Hospital del Mar Medical Research Institute (IMIM) and has been published in the journals Archivos de Bronconeumología and Biomedicines.
Més informació "Iron supplements improve physical fitness and quality of life in COPD patients"
16/09/2021 - Press release
Older adults who are overweight or obese who stick most closely to the Mediterranean diet preserve their cognitive performance and even improve their abilities after three years, according to a study led by researchers at the Hospital del Mar Medical Research Institute and the CIBEROBN, published in the journal Clinical Nutrition. Memory improvements are proportional to the level of adherence to the Mediterranean diet, weight loss and increased physical activity. At the same time, these changes translate into improvements in people's quality of life. The work is based on the PREDIMED-PLUS trial and shows that women and people with less education gain less benefit on a cognitive level from this type of dietary intervention. This leads the researchers to support the personalization of these approaches in order to maximize the benefit.
Més informació "The Mediterranean diet helps improve cognitive function and memory"
12/08/2021 - Press release
A study led by doctors and researchers from Hospital del Mar, the Hospital del Mar Medical Research Institute (IMIM), and CIBER Oncology (CIBERONC) has demonstrated the role a protein, neuregulin, plays in generating resistance to the most common treatment for HER2-positive breast cancer, one of the most aggressive types. The study, published in the journal Clinical Cancer Research, and in which leading Italian researchers Luca Gianni from the Fondazione Gianni Bonnadonna and Giampaolo Bianchini from the IRCCS Ospedale San Raffaele have collaborated, has identified that in patients with high levels of this protein, the success rate with the monoclonal antibody trastuzumab, the first-line drug, drops. Conversely, when combined with another monoclonal antibody, pertuzumab, the situation is reversed and full pathological response levels are restored.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
